All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
During the 4th National Cancer Research Institute (NCRI) AML Academy Meeting, the AML Hub was pleased to speak to Pramila Krishnamurthy, King’s College Hospital NHS Foundation Trust, London, UK. We asked, What does the future hold for patients with relapsed acute myeloid leukemia (AML)?
What does the future hold for patients with relapsed AML?
Krishnamurthy discusses the changing landscape of frontline therapy and challenges facing clinicians. Focusing on topics such as the use of novel doublet and triplet combination agents, menin inhibitors, and the potential of immune and CAR T-cell therapies, Krishnamurthy presents her thoughts on what the future holds for patients with relapsed AML, including the importance of clinical trials specifically for this subgroup.
2022 ELN recommendations for the management of AML in adults
A summary of the updated guidelines for the management of AML, from the same publication in Blood, by Döhner et al. on behalf of the ELN.
Clinical practice guidelines on infectious complications of targeted drugs and biotherapies: European Conference on Infections in Leukaemia (ECIL)
At the 9th European Conference on Infections in Leukaemia (ECIL 9), the risk of infections and febrile...
Subscribe to get the best content related to AML delivered to your inbox